Previous 10 | Next 10 |
2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers PR Newswire SOUTH SAN FRANCISCO, Calif. and HOUSTON , Dec. 8, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: R...
2023-11-30 19:09:17 ET Summary RIGL's net loss continues to narrow, down to $5.7M in Q3'23. RIGL's patent infringement suit with Annora Pharma is in play, but I don't expect a near-term issue on Tavalisse market exclusivity, because the case will take time to play out. A retur...
2023-11-07 18:26:04 ET Rigel Pharmaceuticals, Inc. (RIGL) Q3 2023 Earnings Conference Call November 07, 2023 04:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary Raul Rodriguez - President & Chief Execut...
2023-11-07 16:15:05 ET More on Rigel Pharmaceuticals Rigel: Incremental Progress, But Major Financial Risks Remain Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals Historical earnings data for Rigel Pharmaceuticals Financial information for Rigel ...
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE ® net product sales of $24.5 million and REZLIDHIA ® net product sales of ...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Rigel Pharmaceuticals Inc. (RIGL) is expected to report $-0.06 for Q3 2023
Rigel to Present at the Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, will pr...
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition PR Newswire -- Growing body of data on REZLIDHIA ® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...